A Phase II, Open Label, Two-Arm Study of Therapeutic Iobenguane (131I) as Single Agent or in Combination with Vorinostat For Recurrent or Progressive High-Risk Neuroblastoma Subjects (Optimum Trial)

Is this Study for You?

Let's Get Started!

Details
Age

Child

Locations

Childrens Hospital Colorado

Principal Investigator
Photograph of Margaret Macy

Margaret Macy

Study ID

Protocol Number: 16-0742

More information available at ClinicalTrials.gov: NCT03561259

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers